Revvity Signals - Drug Discovery

News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

AbbVie Begins Construction of New API Manufacturing Plant in North Chicago

Tuesday, September 30, 2025

AbbVie has started building a new active pharmaceutical ingredient API manufacturing plant in North Chicago Illinois The project marks a key step in expanding AbbVies US manufacturing network capabilities and production capacity

Er-Kim to Distribute Nulibry® and Zokinvy® in EMEA and Eurasian Markets

Thursday, September 25, 2025

ErKim an international pharmaceutical company focused on commercialising novel therapies in the EMEA region has signed an agreement with Sentynl Therapeutics Inc to distribute Nulibry fosdenopterin and Zokinvy lonafarnib

TegMine Therapeutics Collaborates with Boehringer Ingelheim to Advance 2-Factor Antibody System for Cancer

Wednesday, September 24, 2025

TegMine Therapeutics a biotechnology company specialising in precision oncology has entered a research and development collaboration with Boehringer Ingelheim The partnership will use TegMines proprietary Factor Antibody System

Merck and Siemens Strengthen Partnership to Drive AI and Data-Led Drug Development

Wednesday, September 24, 2025

Merck a global science and technology company has expanded its strategic partnership with Siemens through a new Memorandum of Understanding MoU The agreement aims to accelerate digital transformation

Sanofi’s SAR446268 Therapy Receives US Fast Track Designation for Non-Congenital Myotonic Dystrophy Type 1

Tuesday, September 23, 2025

The US Food and Drug Administration FDA has granted Fast Track designation to SAR Sanofis AAV gene therapy for juvenile and adult noncongenital myotonic dystrophy type DM The Fast Track process is designed to accelerate the development and review of...

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Friday, September 19, 2025

Minovia Therapeutics Ltd a clinicalstage biotechnology company focused on therapies for mitochondrial diseases and agerelated decline has received Fast Track Designation FTD from the US Food and Drug Administration

Thryv Therapeutics secures FDA IND clearance for THRV-1268 in Long QT Syndrome

Thursday, September 18, 2025

Thryv Therapeutics Inc a clinicalstage biotechnology company developing serum glucocorticoid inducible kinase SGK inhibitors for cardiovascular diseases has received clearance from the US Food

Roche signs merger agreement to acquire 89bio and its phase 3 FGF21 analogue for moderate to severe MASH

Thursday, September 18, 2025

Roche has entered into a definitive merger agreement to acquire bio Inc a Nasdaqlisted clinicalstage biopharmaceutical company developing therapies for liver and cardiometabolic diseases The deal is expected to close in the fourth quarter of

VarmX Enters Strategic Collaboration and Option Agreement with CSL to Advance Novel Coagulation Treatment

Wednesday, September 17, 2025

VarmX a biotechnology company focused on therapies for bypassing direct oral anticoagulants targeting activated factor Xa FXa DOACs and inherited coagulation disorders has formed

Anti-MTBR Tau Antibody Etalanetug Receives FDA Fast Track Designation

Wednesday, September 17, 2025

Eisai Co Ltd has announced that etalanetug development code E an investigational antiMTBR microtubule binding region tau antibody has been granted Fast Track designation by the US Food and Drug Administration